[{"id":"437a0b30-c17c-4f59-99bc-c3201c096d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05830097","created_at":"2023-04-26T14:04:47.548Z","updated_at":"2024-07-02T16:35:26.556Z","phase":"Phase 1/2","brief_title":"A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05830097","lead_sponsor":"Coherent Biopharma (Hefei) Co., Ltd.","biomarkers":" FOLR1 • TRPV6","pipe":"","alterations":" ","tags":["FOLR1 • TRPV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1019"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-12-12"},{"id":"cbdac200-fe8e-4b55-ad12-6ac910522add","acronym":"PRECISIONV","url":"https://clinicaltrials.gov/study/NCT00261378","created_at":"2021-01-18T00:53:16.721Z","updated_at":"2024-07-02T16:36:27.626Z","phase":"Phase 2","brief_title":"Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation","source_id_and_acronym":"NCT00261378 - PRECISIONV","lead_sponsor":"Boston Scientific Corporation","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DC Bead (E7040)"],"overall_status":"Completed","enrollment":" Enrollment 212","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 01/01/2008","study_completion_date":" 01/01/2008","last_update_posted":"2021-07-21"},{"id":"3394a8c8-2d3a-47af-8e85-851b55f69cb0","acronym":"CerebralEDV","url":"https://clinicaltrials.gov/study/NCT02766699","created_at":"2021-01-18T13:34:05.356Z","updated_at":"2024-07-02T16:36:56.125Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)","source_id_and_acronym":"NCT02766699 - CerebralEDV","lead_sponsor":"Engeneic Pty Limited","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • doxorubicin hydrochloride • doxorubicin encapsulated nanocells (EGFREDVDox)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 10/25/2016","start_date":" 10/25/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-08-29"},{"id":"cc1b6bdf-3c1d-4477-901e-9bfb667da8fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02015754","created_at":"2021-01-18T09:13:17.696Z","updated_at":"2024-07-02T16:37:12.878Z","phase":"Phase 2","brief_title":"Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer","source_id_and_acronym":"NCT02015754","lead_sponsor":"Yale University","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • DC Bead (E7040)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 06/02/2015","primary_completion_date":" 06/02/2015","study_txt":" Completion: 12/13/2016","study_completion_date":" 12/13/2016","last_update_posted":"2018-03-22"},{"id":"b869532b-4b47-474d-a303-9692e3af1ab0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02838225","created_at":"2021-01-18T13:55:41.484Z","updated_at":"2024-07-02T16:37:30.412Z","phase":"Phase 2","brief_title":"DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer","source_id_and_acronym":"NCT02838225","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Pinorubin (pirarubicin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-07-20"}]